Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

Inclusion Criteria: * Age between 55 and 85 years old * Patients with chronic cerebrovascular disease, who have modified Fazekas scale grade 2 \~ 3 * Patients wtih a diagnosis of MCI * MOCA-K of 23 or less * Patients who provided a signed written informed consent form Exclusion Criteria: * Patiens who are uneducated or illiterate * Patiens previously treated with dementia * Patients who received a nootropic agent or thyroid hormone within 4 weeks of visit 1 * Patients with cognitive impairment due to diseases other than cerebrovascular disease * Patients with severe depression, schizophrenia, alcoholism, and drug dependence